CACNA1B
ENSG00000148408
Target class
Ion channel
Chromosome
9
Approved drugs
9
Clinical candidates (approved and in development)
16
- Approved drugs
- 9
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 16
- Chemical probe available
- No
- Target name
- CACNA1B
- Gene name
- Calcium voltage-gated channel subunit alpha1 B
- Gene symbol
- CACNA1B
- Previous gene symbols
- CACNL1A5
- Protein name
- Voltage-dependent N-type calcium channel subunit alpha-1B (Brain calcium channel III) (BIII) (Calcium channel, L type, alpha-1 polypeptide isoform 5) (Voltage-gated calcium channel subunit alpha Cav2.2)
- Cav2.2
- CACNN
- Gene biotype
- Protein coding
- Gene family
- EF-hand domain containing|Calcium voltage-gated channel alpha1 subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 15
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 51.5
- Tissue specificity (Gini)
- 0.822
- Tissue specificity (tau)
- 0.932
- KEGG gene identifiers
- hsa:774
- Reactome pathways
- R-HSA-112308
- Protein interaction confidence
- 0.828378
- Protein interaction partners
- 45
- End position
- 138124624
- Start position
- 137877782
- Chromosome
- 9
- Strand
- Forward
- Membrane
- Multi-pass membrane protein .
- Acrosome
- Cytosol
- Equatorial segment
Publication evidence
- PubMed 34234349
- Tissue specificity (tau)
- 0.932021
- Expression inequality (Gini)
- 0.821837
Expression in transcripts per million
- Brain - Cerebellum
- 51.5
- Brain - Cerebellar Hemisphere
- 45.97
- Brain - Cortex
- 19.5
- Brain - Frontal Cortex (BA9)
- 17.14
- Pituitary
- 15.54
Expression in transcripts per million
- Brain - Cerebellum51.5
- Brain - Cerebellar Hemisphere45.97
- Brain - Cortex19.5
- Brain - Frontal Cortex (BA9)17.14
- Pituitary15.54
- Brain - Nucleus accumbens (basal ganglia)12.2
- Testis11.99
- Brain - Anterior cingulate cortex (BA24)10.55
- Brain - Hypothalamus9.89
- Brain - Caudate (basal ganglia)9.48
- Brain - Putamen (basal ganglia)7.74
- Brain - Spinal cord (cervical c-1)6.6
- Brain - Amygdala5.33
- Brain - Hippocampus5.08
- Brain - Substantia nigra2.7
- Colon - Sigmoid0.88
- Prostate0.71
- Thyroid0.49
- Fallopian Tube0.44
- Colon - Transverse0.36
- Stomach0.32
- Cervix - Endocervix0.22
- Esophagus - Muscularis0.21
- Vagina0.2
- Esophagus - Gastroesophageal Junction0.17
And 29 more, listed on the interactive page.
- GO:0007268
- GO:0050804
- GO:1904645
- GO:0005886
- GO:0005891
- GO:0016020
- GO:0001540
- GO:0005245
- GO:0005515
- GO:0008331
Related records
Trials (1,273)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
Drugs (18)
- Atagabalin Voltage-gated calcium channel modulator
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- CNV2197944 Voltage-gated N-type calcium channel alpha-1B subunit blocker
- Elpetrigine Voltage-gated N-type calcium channel alpha-1B subunit blocker
- Gabapentin Voltage-gated calcium channel modulator
- Gabapentin enacarbil Voltage-gated calcium channel modulator
- Imagabalin Voltage-gated calcium channel modulator
- Levetiracetam Voltage-gated N-type calcium channel alpha-1B subunit blocker
- Phloroglucinol Voltage-gated calcium channel blocker
- Pregabalin Voltage-gated calcium channel modulator
- Ralfinamide Voltage-gated N-type calcium channel alpha-1B subunit blocker
- Suloctidil Voltage-gated calcium channel blocker
- Terodiline Voltage-gated calcium channel blocker
- Terodiline hydrochloride Voltage-gated calcium channel blocker
- Z160 Voltage-gated N-type calcium channel alpha-1B subunit blocker
- Ziconotide Voltage-gated N-type calcium channel alpha-1B subunit blocker
- Ziconotide acetate Voltage-gated N-type calcium channel alpha-1B subunit blocker